Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months.

Emerging therapeutic approaches target the MAPK/ERK signalling pathway using MEK inhibitors such as trametinib and selumetinib. However, clinical progress faces obstacles including inadequate blood-brain barrier penetration and dose-limiting toxicity concerns.

Researchers Noemi Bognanni, Graziella Vecchio, and their team evaluated two cationic cyclodextrin polymers as potential nanocarriers for treating glioblastoma. The polymers’ architecture and positive charge enable effective drug encapsulation and membrane interactions.

Referenced Research: “Positively Charged Polymers Based on Cyclodextrins for Trametinib and Selumetinib Delivery in Glioblastoma Cancer” — published in ChemMedChem by Wiley Online Library (2026)